GlassScriptPhysician profile
Jill C Miller
NPI 1811148422
$4,037.39
in general payments reported to CMS, 2019-2025
30 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $113 · 2021: $467 · 2022: $543 · 2023: $1,318 · 2024: $684 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,405.98 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $606.61 | 2022-2025 | Sublocade |
| Acadia Pharmaceuticals INC | $534.38 | 2023 | Nuplazid |
| Novo Nordisk INC | $468.42 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Lilly USA, LLC | $307.36 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $219.38 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.11 | 2019-2025 | Jardiance, Synjardy |
| Tactile Systems Technology INC | $197.02 | 2021 | |
| Braeburn INC. | $196.09 | 2023-2025 | Brixadi |
| Pfizer INC. | $157.51 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $134.24 | 2019-2023 | Belsomra, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $129.05 | 2019-2025 | Trintellix |
| Currax Pharmaceuticals LLC | $108.04 | 2021-2025 | Nexletol, Onzetra Xsail, Contrave |
| Amgen INC. | $88.33 | 2019-2025 | Prolia, Evenity |
| E.R. Squibb & Sons, L.L.C. | $86.79 | 2019-2024 | Eliquis |
| Glaxosmithkline, LLC. | $71.51 | 2022-2024 | Shingrix, Arexvy, Bexsero |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $66.04 | 2019-2024 | Farxiga |
| Alkermes, INC. | $62.45 | 2022-2025 | Vivitrol |
| Bayer Healthcare Pharmaceuticals INC. | $57.85 | 2021-2024 | |
| Exact Sciences Corporation | $49.25 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $43.53 | 2021-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.59 | 2024-2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $33.69 | 2019 | |
| Mylan Specialty L.P. | $25.68 | 2024 | Yupelri |
| Nalpropion Pharmaceuticals LLC | $25.19 | 2019 | |
| Allergan, INC. | $25.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.71 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $18.80 | 2022 | |
| Astellas Pharma US INC | $17.83 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $17.08 | 2022 | |
| Horizon Therapeutics Plc | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.